CVS Boosts Dividend By 21% And Raises 2016 Outlook

Noah Kiedrowski - Contributor - Biotech


I have posted that CVS presented a compelling investment opportunity in the healthcare space. This premise was rooted in the fact that CVS has been highly acquisitive, continuous robust growth rate, growing its dividends over time and has an aggressive share buyback program. CVS recently reported robust earnings and continued to drive and position itself for long-term success. With its recent acquisitions and partnerships, specifically, the acquisition Target’s pharmacies and Omnicare will significantly expand its footprint and ability to dispense prescriptions to the general public and in assisted living and long-term care facilities that serve the senior patient population. As the United States continues to absorb an aging population alongside growing overall healthcare costs, more specifically prescription drug costs, CVS looks poised to benefit and continue to outperform the broader market. The most recent earnings report, rise in its 2016 outlook and a 21% boost in its dividend payout underscores this premise. I content that CVS will continue to deliver continued growth and positioning for long-term success. Continue reading "CVS Boosts Dividend By 21% And Raises 2016 Outlook"

2 Healthcare Stocks To Avoid And 2 I Like

As America ages, healthcare is going to be an important issue. How companies approach this is going to make a big difference to their bottom line.

The new Affordable Care Act, which is slowly being implemented, is another dimension that will have to be factored into the future. How companies adapt and make money in the future may have more to do with how they do business, rather than the drugs they are pushing.

Today, I'll be looking at four stocks, two that are in strong bullish trends according to the Trade Triangle technology, and two that are in downtrends.

From the long side based on the Trade Triangle technology:
Abbott Laboratories (NYSE:ABT)
Johnson & Johnson (NYSE:JNJ)

From the short side based on the Trade Triangle technology:
Amgen Inc. (NASDAQ:AMGN)
Pfizer, Inc. (NYSE:PFE)

Every success with MarketClub,
Adam Hewison
Co-Creator, MarketClub

Bloomberg BNN CNBC FOX

Adam appears frequently on the following financial news channels as a guest expert. Click on any cable logo to watch Adam's latest appearance.

Drugstore Wars: Walgreen Vs. CVS

I hope I'm not dating myself too much, but I remember when the neighborhood chain drugstore was almost a one-stop shop for human needs.

For example, you dropped off your film to get developed. You could get the ointment for that embarrassing itch. You could even get a BLT and some fries. (Not necessarily in that order.)

The BLTs and fries are long gone, but the chain drugstore on the neighborhood corner has continued to evolve and embed itself into our daily lives. And it will continue to do so in an even bigger way going forward.

By far, the two biggest players in the drugstore space are Walgreen Co. (NYSE: WAG) and CVS Caremark (NYSE: CVS). If two-thirds of the Earth is covered by water, the remaining third is covered by these two companies. But which stock makes the most sense for your portfolio? Continue reading "Drugstore Wars: Walgreen Vs. CVS"

Will Amazon (AMZN) Make It To $400?

Hello traders everywhere! Adam Hewison here, President of and Co-creator of MarketClub, with your mid-day market update for Friday, the 1st of November.

Last month was a great month for many investors, myself included, as all of my stocks moved in a favorable direction. I see little reason to change my analysis of the markets as I expect them to continue to move higher in November. This is partly due to the Fed continuing with its $85 billion a month bond buying binge. With Apple's iPad going on sale worldwide today, I see great sales coming for the retail sector as the public buys into the holiday season.

MarketClub's mid-day update for Friday, the 1st of November

One major concern on the horizon is the roll-out of the “Affordable Care Act” (Obamacare), which is going to have an effect on one sixth of the economy here in the United States. So far, the roll-out has been a big disappointment, as many people are seeing potential increases in their insurance rates with this new plan. If rates increase substantially, then that money will be coming out of the economy, which will not necessarily be a good thing. Continue reading "Will Amazon (AMZN) Make It To $400?"